GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » 3-Year Book Growth Rate

PMN (ProMIS Neurosciences) 3-Year Book Growth Rate : 0.00% (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences 3-Year Book Growth Rate?

ProMIS Neurosciences's Book Value per Share for the quarter that ended in Jun. 2024 was $-0.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of ProMIS Neurosciences was 304.90% per year. The lowest was -88.10% per year. And the median was -33.55% per year.

Competitive Comparison of ProMIS Neurosciences's 3-Year Book Growth Rate

For the Biotechnology subindustry, ProMIS Neurosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProMIS Neurosciences's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's 3-Year Book Growth Rate falls into.


ProMIS Neurosciences 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

ProMIS Neurosciences  (NAS:PMN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

ProMIS Neurosciences 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » 3-Year Book Growth Rate
Comparable Companies
EYEN NXTC TARA UNCY KZR AEON LTRN AKTX FGEN PVCT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 ALNY XBRU:UCB XBRU:ARGX XKRX:068270 BNTX
Traded in Other Exchanges
23J0:Germany
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
Website
https://www.promisneurosciences.com
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Executives
Madge K. Shafmaster director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel officer: Chief Medical Officer C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar 10 percent owner 33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel director, officer: Chief Executive Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury officer: Principal Accounting Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant officer: Chief Operating Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman director, officer: Chief Scientific Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan officer: Chief Development Officer PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams director, officer: Chairman and CEO C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory director 830 WINTER STREET, WALTHAM MA 02451
Neil K Warma director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman director 4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2